Calcimimetics in CKD—results from recent clinical studiesReportar como inadecuado




Calcimimetics in CKD—results from recent clinical studies - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Pediatric Nephrology

, 23:1721

First Online: 02 July 2008Received: 20 March 2008Revised: 03 May 2008Accepted: 05 May 2008

Abstract

Secondary hyperparathyroidism sHPT is a frequent complication in patients with chronic kidney disease CKD and a known contributor to the development of vascular calcification and renal osteodystrophy CKD–BMD. Secondary hyperparathyroidism is also related to increased cardiovascular mortality in CKD patients. With the discovery that molecules can modulate the calcium-sensing receptor CaR of the parathyroid gland, new treatment options are now available to control sHPT. Calcimimetics activate the CaR and—by increasing its sensitivity to calcium—can effectively decrease parathyroid hormone PTH secretion. Calcimimetic treatment with cinacalcet has resulted in an effective lowering of PTH levels in both animal and clinical studies. Most clinical studies have been performed in dialysis patients, and only a few studies have been carried out in patients with CKD stage 3 and 4 and renal transplant patients. In haemodialysis patients with sHPT, cinacalcet treatment could increase the number of patients achieving National Kidney Foundation Kidney Disease Outcomes Quality Initiative targets PTH, calcium, phosphate compared to standard therapy. In stage 3 and 4 CKD patients, cinacalcet has been reported to reduce PTH levels, however, at the expense of increasing phosphate serum levels. Several small studies have reported that calcimimetics reduced PTH levels and hypercalcaemia after renal transplantation. In addition, two studies on paediatric dialysis patients with sHPT reported effective PTH lowering. This review summarizes recent clinical studies with cinacalcet treatment in CKD patients.

KeywordsCalcimimetics Cinacalcet Chronic kidney disease End-stage renal disease Pediatric patients Review Secondary hyperparathyroidism J. Floege has received lecture and consulting fees from Amgen and is performing collaborative studies both clinically and experimentally with Amgen.

Download fulltext PDF



Autor: Georg Schlieper - Jürgen Floege

Fuente: https://link.springer.com/







Documentos relacionados